Expression of absent in melanoma 2 in breast cancer and its clinical significance
-
摘要:目的
探讨乳腺癌组织中黑色素瘤缺乏因子2(AIM2)的表达及其临床意义。
方法选择乳腺癌患者118对癌组织及癌旁组织, 采用免疫组化方法检测癌组织及癌旁组织中AIM2的表达，分析癌组织中AIM2表达与临床病理特征的关系。采用Kaplan-Meier生存曲线分析AIM2蛋白与乳腺癌患者生存期的关系; 采用COX回归分析探讨乳腺癌患者无瘤生存期及总生存期的影响因素。
结果乳腺癌组织中AIM2阳性率低于癌旁组织，差异有统计学意义(P < 0.05);乳腺癌组织免疫组化评分低于癌旁组织，差异有统计学意义(P < 0.05);癌组织中AIM2表达与肿瘤直径、淋巴结转移、临床分期和脉管内癌栓相关(P < 0.05);Kaplan-Meier分析结果表明，乳腺癌组织中AIM2低表达患者有更短的总生存期及无瘤生存期(χ2=9.072、6.101, P=0.004、0.015);多因素Cox回归分析显示, AIM2(OR=3.387, 95%CI: 1.033~21.440, P=0.047)是乳腺癌患者无瘤生存期的独立影响因素。
结论AIM2在乳腺癌组织中低表达，提示乳腺癌患者预后不良。
Abstract:ObjectiveTo investigate the expression and clinical significance of absent in melanoma 2 (AIM2) in breast cancer tissues.
MethodsA total of 118 pairs of cancer tissues and adjacent tissues from breast cancer patients were selected. Immunohistochemistry was used to detect the expression of AIM2 in cancer tissues and adjacent tissues, the relationships between AIM2 expression in cancer tissues and clinicopathological characteristics were analyzed. Kaplan-Meier survival curve was used to analyze the relationship between AIM2 protein and survival of breast cancer patients; COX regression analysis was used to explore the influencing factors of tumor-free survival and overall survival of breast cancer patients.
ResultsThe positive rate of AIM2 in breast cancer tissues was lower than that in adjacent tissues, and the difference was statistically significant (P < 0.05); the immunohistochemical score of breast cancer tissue was lower than that of adjacent tissue, and the difference was statistically significant (P < 0.05); the expression of AIM2 in cancer tissue was correlated with tumor diameter, lymph node metastasis, clinical stage and intravascular tumor thrombus (P < 0.05); Kaplan-Meier analysis showed that patients with low AIM2 expression in breast cancer tissue had shorter overall survival and disease-free survival (χ2=9.072, 6.101; P=0.004, 0.015); COX multivariate regression analysis showed that AIM2 (OR=3.387; 95%CI, 1.033 to 21.440; P=0.047) was an independent influencing factor of tumor-free survival in breast cancer patients.
ConclusionAIM2 is lowly expressed in breast cancer tissues, and it suggests that the prognosis of breast cancer patients is poor.
-
Keywords:
- breast cancer /
- absent in melanoma 2 /
- clinicopathological features /
- prognosis
-
-
![]()
图 1 免疫组化方法检测乳腺癌组织和癌旁组织中AIM2的表达
A: 乳腺癌组织中AIM2的表达; B: 癌旁组织中AIM2的表达; C: AIM2在乳腺癌组织和癌旁组织中免疫组化评分比较。放大倍数为200倍，免疫组化具体方法为SP法。
表 1 AIM2表达与乳腺癌临床病理特征的关系
临床病理参数 分类 n AIM2表达 χ2 P 高表达 低表达 年龄 < 50岁 62 30 32 0.136 0.712 ≥50岁 56 29 27 组织学分级 Ⅰ级 17 11 6 1.718 0.190 Ⅱ~Ⅲ级 101 48 53 组织学类型 非特殊型浸润性癌 114 58 56 0.259 0.619 特殊型浸润性癌 4 1 3 神经侵犯 有 32 15 17 0.172 0.679 无 86 44 42 脉管内癌栓 有 34 12 22 4.132 0.042 无 84 47 37 分子分型 较高风险型 39 18 21 0.345 0.557 较低风险型 79 41 38 TNM分期 Ⅰ~Ⅱ期 92 53 39 9.669 0.002 Ⅲ期 26 6 20 肿瘤直径 ≤2 cm 61 25 36 4.106 0.043 >2 cm 57 34 23 淋巴结转移 无 93 41 52 6.141 0.013 有 25 18 7 较高风险型: 三阴型+HER-2过表达型; 较低风险型: Luminal A型+Luminal B型。 
下载: 导出CSV
表 2 乳腺癌患者无瘤生存期影响因素的COX回归分析
参数 单因素分析 多因素分析 HR(95%CI) P HR(95%CI) P 年龄 1.677(0.412~5.421) 0.711 — — 病理分级 0.567(0.112~6.110) 0.605 — — 组织学类型 2.610(0.312~31.921) 0.401 — — 神经侵犯 2.011(0.310~11.124) 0.436 — — 分子分型 0.510(0.420~2.410) 0.217 — — TNM分期 0.191(0.055~0.847) 0.007 0.227(0.107~0.733) 0.019 AIM2蛋白 5.574(1.069~24.110) 0.036 3.387(1.033~21.440) 0.047 脉管内癌栓 6.741(1.022~25.133) 0.048 5.112(0.994~19.433) 0.062 肿瘤直径 5.465(1.166~11.796) 0.044 4.229(0.937~16.440) 0.077 淋巴结转移 4.958(1.648~15.737) 0.029 3.982(1.220~19.407) 0.038
下载: 导出CSV
表 3 乳腺癌患者总生存期影响因素的COX回归分析
参数 单因素分析 多因素分析 HR(95%CI) P HR(95%CI) P 年龄 1.062(0.201~5.357) 0.944 — — 病理分级 0.942(0.168~9.778) 0.919 — — 组织学类型 5.838(0421~77.47) 0.230 — — 神经侵犯 2.142(0.246~29.557) 0.552 — — 分子分型 1.274(0.347~11.288) 0.613 — — TNM分期 0.069(0.015~0.745) 0.033 0.201(0.020~0.867) 0.040 AIM2蛋白 5.277(0.687~15.147) 0.044 3.487(0.896~59.489) 0.077 脉管内癌栓 8.633(0.897~88.247) 0.097 — — 肿瘤直径 3.498(0.968~12.486) 0.075 — — 淋巴结转移 4.898(1.557~13.745) 0.027 4.748(1.179~14.338) 0.045
下载: 导出CSV
-
[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
[2] ZHANG M D, JIN C Y, YANG Y J, et al. AIM2 promotes non-small-cell lung cancer cell growth through inflammasome-dependent pathway[J]. J Cell Physiol, 2019, 234(11): 20161-20173. doi: 10.1002/jcp.28617
[3] SO D, SHIN H W, KIM J, et al. Cervical cancer is addicted to SIRT1 disarming the AIM2 antiviral defense[J]. Oncogene, 2018, 37(38): 5191-5204. doi: 10.1038/s41388-018-0339-4
[4] FARSHCHIAN M, NISSINEN L, SILJAMÄKI E, et al. Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma[J]. Oncotarget, 2017, 8(28): 45825-45836. doi: 10.18632/oncotarget.17573
[5] 方三高, 魏建国, 陈真伟. WHO(2019)乳腺肿瘤分类[J]. 临床与实验病理学杂志, 2020, 36(6): 755-756. https://www.cnki.com.cn/Article/CJFDTOTAL-LSBL202006046.htm [6] 梁黛雯, 王丽雅, 朱晓芳. 黑色素瘤缺乏因子2与银屑病关系的研究进展[J]. 实用临床医药杂志, 2021, 25(2): 122-124. doi: 10.7619/jcmp.20200520 [7] 刘伊偲, 胡容. 黑色素瘤缺乏因子2在炎症、免疫和肿瘤发生发展中的作用[J]. 药物生物技术, 2018, 25(4): 354-358. https://www.cnki.com.cn/Article/CJFDTOTAL-YWSW201804017.htm [8] 郝立肖, 张云艳. AIM2在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(2): 175-178. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZL201702023.htm [9] JIANG L, GE W Y, CUI Y F, et al. The regulation of long non-coding RNA 00958(LINC00958) for oral squamous cell carcinoma (OSCC) cells death through absent in melanoma 2(AIM2) depending on microRNA-4306 and Sirtuin1(SIRT1) in vitro[J]. Bioengineered, 2021, 12(1): 5085-5098. doi: 10.1080/21655979.2021.1955561
[10] QI M, DAI D, LIU J, et al. AIM2 promotes the development of non-small cell lung cancer by modulating mitochondrial dynamics[J]. Oncogene, 2020, 39(13): 2707-2723. doi: 10.1038/s41388-020-1176-9
[11] RIVA G, PECORARI G, BIOLATTI M, et al. PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or-negative head and neck squamous cell carcinomas[J]. Mol Biol Rep, 2019, 46(3): 3333-3347. doi: 10.1007/s11033-019-04795-7
[12] LOZANO-RUIZ B, GONZÁLEZ-NAVAJAS J M. The emerging relevance of AIM2 in liver disease[J]. Int J Mol Sci, 2020, 21(18): 6535. doi: 10.3390/ijms21186535
[13] XU M L, WANG J F, LI H R, et al. AIM2 inhibits colorectal cancer cell proliferation and migration through suppression of Gli1[J]. Aging (Albany NY), 2020, 13(1): 1017-1031.
[14] ZHOU R, SUN J, HE C P, et al. CCL19 suppresses gastric cancer cell proliferation, migration, and invasion through the CCL19/CCR7/AIM2 pathway[J]. Hum Cell, 2020, 33(4): 1120-1132. doi: 10.1007/s13577-020-00375-1
[15] 郑盼盼, 肖文璐, 黄浩, 等. 黑色素瘤缺乏因子2在胆管癌组织中的表达及其临床意义[J]. 中国免疫学杂志, 2020, 36(9): 1053-1057. doi: 10.3969/j.issn.1000-484X.2020.09.006 [16] 武少贤, 李源, 郑盼盼, 等. 黑色素瘤缺乏因子2在胰腺癌组织的表达及其临床意义[J]. 中华实验外科杂志, 2019, 36(9): 1668-1671. doi: 10.3760/cma.j.issn.1001-9030.2019.09.041 [17] MALINOVSKAYA E M, ERSHOVA E S, OKOROKOVA N A, et al. Ribosomal DNA as DAMPs signal for MCF7 cancer cells[J]. Front Oncol, 2019, 9: 445.
[18] SU S C, ZHAO J H, XING Y, et al. Immune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophages[J]. Cell, 2018, 175(2): 442-457, e23.
[19] LI Y Q, WANG W, LI A X, et al. Dihydroartemisinin induces pyroptosis by promoting the AIM2/caspase-3/DFNA5 axis in breast cancer cells[J]. Chem Biol Interact, 2021, 340: 109434.
[20] LIU Z Y, YI J, LIU F G. The molecular mechanism of breast cancer cell apoptosis induction by absent in melanoma (AIM2)[J]. Int J Clin Exp Med, 2015, 8(9): 14750-14758.
[21] 黄智, 罗亮, 沈攀. 黑色素瘤缺乏因子2和赖氨酰氧化酶在结直肠癌组织中的表达及与预后的关系[J]. 中国现代普通外科进展, 2021, 24(1): 5-9, 14. https://www.cnki.com.cn/Article/CJFDTOTAL-PWJZ202101003.htm [22] CHEN S L, LIU L L, LU S X, et al. HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis[J]. Mol Oncol, 2017, 11(9): 1225-1240.
计量
- 文章访问数: 152
- HTML全文浏览量: 53
- PDF下载量: 5
苏公网安备 32100302010246号